Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453682 | 0.84 | NOTUM (0.50) | NOTUMALDH1A1CHRM4MEN1KMT2A | |
| SCHEMBL441063 | 0.78 | NOTUM (0.56) | NOTUMCHRM4 | |
| SCHEMBL438088 | 0.78 | NOTUM (0.56) | NOTUMCHRM4POLBRXFP1 | |
| SCHEMBL31618430 | 0.74 | PDPK1 (0.38) | ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL22651223 | 0.73 | HSD17B10 (0.37) | NOTUMALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL31618229 | 0.72 | PDPK1 (0.34) | ALDH1A1MEN1KMT2A | |
| SCHEMBL438085 | 0.71 | NOTUM (0.77) | NOTUMALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL438091 | 0.71 | GPR35 (0.37) | ALDH1A1CHRM4MEN1KMT2AMAPT | |
| SCHEMBL31618452 | 0.67 | APLNR (0.35) | ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL22651286 | 0.66 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616471-B1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | BARBOSA JOSEPH (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | BARBOSA JOSEPH (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2012037141-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, GLA, CES1 | NOTUM 1/4885ALDH1A1 1305/4885CHRM4 1191/4885 |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, GLA, CES1 | NOTUM 1/4885ALDH1A1 1305/4885CHRM4 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.